A comprehensive review of rapid-onset opioids for breakthrough pain

CNS Drugs

Volumn 26, Issue 6, 2012, Pages 509-535

  Smith, Howard ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Cancer pain; Fentanyl; Opioid analgesics; Pain; Routes of administration

Indexed keywords

FENTANYL; FENTANYL CITRATE; OPIATE; SHORT ACTING DRUG; TAIFUN; UNCLASSIFIED DRUG;

AEROSOL; APPLICATION SITE REACTION; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL EFFECTIVENESS; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HUMAN; INFLUENZA; MUCOSAL ADMINISTRATION; NAUSEA; NOSE IRRITATION; NOSE OBSTRUCTION; PATIENT PREFERENCE; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; STOMATITIS; SYSTEMATIC REVIEW; VERTIGO; VOMITING;

BREAKTHROUGH PAIN; CHRONIC PAIN; DRUG ADMINISTRATION ROUTES; FENTANYL; HUMANS; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84861894815     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11630580-000000000-00000     Document Type: Review

References (88)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990; 41 (3): 273-81 (Pubitemid 20187930)
2. Christrup LL, Lundorff L, Werner M. Novel formulations and routes of administration for opioids in the treatment of breakthrough pain. Therapy 2009; 6: 695-706
3. Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain: an international survey. Palliat Med 2004; 18 (3): 177-83 (Pubitemid 38771657)
4. Portenoy RK, Bruns D, Shoemaker B, et al. Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 2010; 6 (2): 97-108
5. Portenoy RK, Bennett DS, Rauck R, et al. Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain 2006; 7 (8): 583-91 (Pubitemid 44137488)
6. Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011; 15 (7): 756-63
7. Taylor DR, Webster LR, Chun SY, et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 2007; 8 (3): 281-8 (Pubitemid 46443468)
8. Dickman A. Integrated strategies for the successful management of breakthrough cancer pain. Curr Opin Support Palliat Care 2011; 5 (1): 8-14
9. Payne R. Recognition and diagnosis of breakthrough pain. Pain Med 2007; 8 Suppl. 1: S3-7 (Pubitemid 46128735)
10. Collins SL, Faura CC, Moore RA, et al. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage 1998; 16 (6): 388-402 (Pubitemid 29006202)
11. Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29 (5 Suppl.): S90-103
12. Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002; 94 (3): 832-9 (Pubitemid 34132314)
13. Zeppetella G. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care (Engl) 2009; 18 (4): 331-7
14. Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000; 88 (3): 287-94
15. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9 (2): 105-21 (Pubitemid 351147828)
16. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998; 90 (8): 611-6 (Pubitemid 28204805)
17. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001; 91 (1-2): 123-30 (Pubitemid 32274181)
18. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007; 96 (12): 1828-33 (Pubitemid 46912022)
19. Portenoy RK, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006; 22 (9): 805-11 (Pubitemid 44627444)
20. Portenoy RK, Messina J, Xie F, et al. Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin 2007; 23 (1): 223-33 (Pubitemid 46191684)
21. Simpson DM, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29 (4): 588-601 (Pubitemid 47016640)
22. Slatkin NE, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J SupportOncol 2007; 5 (7): 327-34 (Pubitemid 350055013)
23. Farrar JT, Messina J, Xie F, et al. A novel 12-week study, with three randomized, double-blind placebo-controlled periods to evaluate fentanyl buccal tablets for the relief of breakthrough pain in opioid-tolerant patients with noncancer-related chronic pain. Pain Med 2010; 11 (9): 1313-27
24. AshburnMA, SlevinKA,Messina J, et al.The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Anesth Analg 2011; 112 (3): 693-702
25. Rauck R, North J, Gever LN, et al. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol 2010; 21 (6): 1308-14
26. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009; 25 (12): 2877-85
27. Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med 2010; 24 (3): 286-93
28. Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 μg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Ther 2009; 31 (6): 1177-91
29. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 2009; 25 (11): 2805-15
30. Portenoy RK, Burton AW, Gabrail N, et al. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010; 151 (3): 617-24
31. Taylor D, Galan V, Weinstein SM, et al. Fentanyl pectin nasal spray in breakthrough cancer pain. J Support Oncol 2010; 8 (4): 184-90
32. Davies A, Sitte T, Elsner F, et al. Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manage 2011; 41 (2): 358-66
33. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17 (1): 1-12 (Pubitemid 26120810)
34. Nicholson B, Agarwala SS. Opioid delivery in the treatment of cancer breakthrough pain: a review of routes of administration. J Opioid Manag 2011; 7 (1): 69-79
35. Walker G, Wilcock A, Manderson C, et al. The acceptability of different routes of administration of analgesia for breakthrough pain. Palliat Med 2003; 17 (2): 219-21 (Pubitemid 36432601)
36. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002; 46 (7): 759-70 (Pubitemid 34803193)
37. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985; 62 (3): 234-41 (Pubitemid 15101870)
38. Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics: a critical review of the implications for treatment. Br J Psychiatry 1987; 151: 210-2 (Pubitemid 17102098)
39. Insler SR, Kraenzler EJ, Licina MG, et al. Cardiac surgery in a patient taking monoamine oxidase inhibitors: an adverse fentanyl reaction. Anesth Analg 1994; 78 (3): 593-7 (Pubitemid 24079389)
40. Food and Drug Administration. FDA warns of potential serious side effects with breakthrough cancer pain drug [online]. Available from URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108994. htm [Accessed 2012 Jan 20]
41. Knill R, Cosgrove JF, Olley PM, et al. Components of respiratory depression after narcotic premedication in adolescents. Can Anaesth Soc J 1976; 23 (5): 449-58
42. Rigg JR, Goldsmith CH. Recovery of ventilatory response to carbon dioxide after thiopentone, morphine and fentanyl in man. Can Anaesth Soc J 1976; 23 (4): 370-82
43. Mercadante S, Ferrera P, Adile C, et al. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose. J Pain Symptom Manage 2011; 42 (3): 464-9
44. Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999; 79 (2-3): 303-12 (Pubitemid 29076765)
45. Passik SD, Kirsh KL. Weighing in on the off-label use of ACTIQ for noncancer-related pain: a recipe for success or a recipe for disaster? Pain Med 2007; 8 (2): 130-3
46. Prime Therapeutics. Study finds 90 percent of Actiq® "lollipop"prescriptions are off-label, 16-1-2007 [online]. Available from URL: http://www.primetherapeutics.com/pdf/Actiq.pdf [Accessed 2012 Jan 20]
47. FDA AERS Reports. Drug report: Actiq®, 2011 [online]. Available from URL: http://www.adverseevents.com/drugdetail.php?AEDrugID=235&BrandName= Actiq [Accessed 2012 Jan 20]
48. FDA. Proposed transmucosal immediate release fentanyl (TIRF) risk evaluation and mitigation strategy (REMS), 2011 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/UCM264065.pdf [Accessed 2012 Jan 20]
49. Actiq® (oral transmucosal fentanyl citrate) [package insert]. Salt Lake City (UT): Cephalon, Inc. 2011
50. Mystakidou K, Katsouda E, Parpa E, et al. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics. Am J Hosp Palliat Care 2005; 22 (3): 228-32 (Pubitemid 40745022)
51. Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 1991; 75 (2): 223-9
52. Egan TD, Sharma A, Ashburn MA, et al. Multiple dose pharmacokinetics of oral transmucosal fentanyl citrate in healthy volunteers. Anesthesiology 2000; 92 (3): 665-73 (Pubitemid 30130168)
53. Streisand JB, Busch MA, Egan TD, et al. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998; 88 (2): 305-9 (Pubitemid 28081188)
54. Darwish M, Kirby M, Robertson Jr P, et al. Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol 2007; 47 (3): 343-50 (Pubitemid 46294716)
55. Darwish M, Kirby M, Robertson Jr P, et al. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers. Clin Ther 2006; 28 (5): 707-14 (Pubitemid 44067265)
56. Vasisht N, Gever LN, Tagarro I, et al. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med 2010; 11 (7): 1017-23
57. Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005; 59 (2): 249-53 (Pubitemid 40208864)
58. Kaasa S, Moksnes K, Nolte T, et al. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manag 2010; 6 (1): 17-26
59. Foster D, Upton R, Christrup L, et al. Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery. Ann Pharmacother 2008; 42 (10): 1380-7
60. Fisher A, Watling M, Smith A, et al. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100-800 μg in healthy volunteers. Int J Clin Pharmacol Ther 2010; 48 (12): 860-7
61. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998; 16 (10): 3238-45 (Pubitemid 28481617)
62. Shaiova L, Lapin J, Manco LS. Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; Actiq) in patients with radiation-induced oral mucositis. Support Care Cancer 2004; 12 (4): 268-73 (Pubitemid 38660750)
63. Payne R, Coluzzi P, Hart L, et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001; 22 (1): 575-83 (Pubitemid 32547445)
64. Fentora® (fentanyl buccal tablet) [package insert]. Salt Lake City (UT): Cephalon, Inc., 2011
65. Durfee S, Messina J, Khankari R. Fentanyl effervescent buccal tablets. Am J Drug Deliv 2006; 4 (1): 1-5
66. Pather SI, Siebert JM, Hontz J, et al. Enhanced buccal delivery of fentanyl using the oravescent drug delivery system. Drug Deliv Technol 2001; 1: 54-7
67. Darwish M, Tempero K, Kirby M, et al. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 μg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin Ther 2006; 28 (5): 715-24 (Pubitemid 44173055)
68. Darwish M, Kirby M, Jiang JG. Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin Pharmacother 2007; 8 (13): 2011-6 (Pubitemid 47514454)
69. Darwish M, Kirby M, Robertson Jr P, et al. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 μg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study. Clin Drug Investig 2010; 30 (6): 365-73
70. Darwish M, Kirby M, Robertson Jr P, et al. Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet 2006; 45 (8): 843-50 (Pubitemid 44182277)
71. Darwish M, Kirby M, Robertson P, et al. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin Drug Investig 2007; 27 (9): 605-11 (Pubitemid 47295719)
72. Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. J Pharm Pharm Sci 1998; 1 (1): 15-30
73. Darwish M, Kirby M, Jiang JG, et al. Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 μg in healthy subjects. Clin Drug Investig 2008; 28 (1): 1-7 (Pubitemid 350274395)
74. Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 2009; 115 (11): 2571-9
75. Fine PG, Messina J, Xie F, et al. Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study. J Pain Symptom Manage 2010; 40 (5): 747-60
76. Vasisht N, Gever LN, Tagarro I, et al. Formulation selection and pharmacokinetic comparison of fentanyl buccal soluble film with oral transmucosal fentanyl citrate: a randomized, open-label, single-dose, crossover study. Clin Drug Investig 2009; 29 (10): 647-54
77. Vasisht N, Gever LN, Tagarro I, et al. Evaluation of the single- and multiple-dose pharmacokinetics of fentanyl buccal soluble film in normal healthy volunteers. J Clin Pharmacol 2010; 50 (7): 785-91
78. Davies A, Finn A, Tagarro I. Intra- and interindividual variabilities in the pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a cross-study analysis. Clin Drug Investig 2011; 31 (5): 317-24
79. Lister N, Warrington S, Boyce M, et al. Pharmacokinetics, safety, and tolerability of ascending doses of sublingual fentanyl, with and without naltrexone, in Japanese subjects. J Clin Pharmacol 2011; 51 (8): 1195-204
80. Nalamachu S, Hassman D, Wallace MS, et al. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 2011; 27 (3): 519-30
81. Uberall MA, Muller-Schwefe GH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 2011; 27 (7): 1385-94
82. Vissers D, Stam W, Nolte T, et al. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010; 26 (5): 1037-45
83. Watts P, Smith A. PecSys: in situ gelling system for optimised nasal drug delivery. Expert Opin Drug Deliv 2009; 6 (5): 543-52
84. Fisher A, Watling M, Smith A, et al. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188. Int J Clin Pharmacol Ther 2010; 48 (2): 138-45
85. Portenoy RK, Raffaeli W, Torres LM, et al. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients. J Opioid Manag 2010; 6 (5): 319-28
86. Akela Pharma Inc. LAB International announces positive fentanyl phase IIA results [online]. Available from URL: http://www.akelapharma.com/modules.php? op=modload&name=News&file=article&sid=34 [Accessed 2012 Apr 20]
87. Vissers DC, Lenre M, Tolley K, et al. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health 2011; 14 (2): 274-81
88. Jacobsen R, Moldrup C, Christrup L. Rationales behind the choice of administration form with fentanyl: Delphi survey among Danish general practitioners. J Opioid Manag 2010; 6 (4): 259-68